Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis

Maturawan Tunhikorn, Photchanun Maneephan, Natcha Tovanakasame, Chalidaporn Kampang, Pusprapa Jandee, Panpanga Sangsuriya, Nuttawut Nuchprayoon · 2026

Read Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis by Maturawan Tunhikorn, Photchanun Maneephan, Natcha Tovanakasame, Chalidaporn Kampang, Pusprapa Jandee, Panpanga Sangsuriya, Nuttawut Nuchprayoon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13569383.txt.

Description

Maturawan Tunhikorn and colleagues tested a dog itch drug in horses with allergic skin disease, publishing the pilot study in 2026. Allergic dermatitis in horses causes intense itching, wounds, and secondary infection, yet evidence for treatments is thin. Oclacitinib, a Janus kinase blocker approved for dogs, targets itch-signalling pathways also found in horses. Sixteen horses aged at least 18 months received the drug daily for 21 days.

Itch scores fell from a median of 5 to 2.5, lesion scores roughly halved, and 15 of 16 horses improved on itch. Blood tests, however, showed rises in liver and kidney markers and falls in white cells, so caution is advised for horses with organ disease. The drug looks effective for equine allergic itch, pending larger safety studies.

Catalog record

CREATORMaturawan Tunhikorn, Photchanun Maneephan, Natcha Tovanakasame, Chalidaporn Kampang, Pusprapa Jandee, Panpanga Sangsuriya, Nuttawut Nuchprayoon
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13569383

Browse the full library · About the Tower of Babel